CARTITUDE-4: Cilta-cel achieves sustained PFS and durable remissions in standard-risk RRMM

SPECIAL EHA 2025

Multiple Myeloma (MM)

CARTITUDE-1: Cilta-cel achieves long-term treatment-free remission in heavily pretreated patients with RRMM

SPECIAL EHA 2025

Multiple Myeloma (MM)

CARTITUDE-4: Cilta-cel demonstrates superior survival outcomes across subgroups in lenalidomide-refractory MM

Multiple Myeloma (MM)

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Lancet Oncol

Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martínez-López J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R

doi: 10.1016/S1470-2045(25)00653-9

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

ASH 2025

Multiple Myeloma (MM)

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

ASH 2025

Multiple Myeloma (MM)

LBA-6: MajesTEC-3: Unprecedented outcomes reinforce teclistamab plus daratumumab as a potential new standard of care for RRMM

ASH 2025

Multiple Myeloma (MM)

Related content

CARTITUDE-1: Cilta-cel achieves long-term treatment-free remission in heavily pretreated patients with RRMM

CARTITUDE-4: Cilta-cel demonstrates superior survival outcomes across subgroups in lenalidomide-refractory MM

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

LBA-6: MajesTEC-3: Unprecedented outcomes reinforce teclistamab plus daratumumab as a potential new standard of care for RRMM

DREAMM-7: Belantamab mafodotin combination achieves superior MRD outcomes in patients with RRMM

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM